Biocompatibles UK Ltd, Farnham Business Park, Weydon Lane, Farnham, Surrey, GU9 8QL, UK.
J Control Release. 2012 Jul 20;161(2):338-50. doi: 10.1016/j.jconrel.2012.01.018. Epub 2012 Jan 21.
Lipiodol-based transarterial chemoembolization (TACE) has been performed for over 3 decades for the treatment of solid tumors and describes the infusion of chemotherapeutic agents followed by embolization with particles. TACE is an effective treatment for inoperable hepatic tumors, especially hypervascular tumors such as hepatocellular carcinoma. Recently, drug eluting beads (DEBs), in which a uniform embolic material is loaded with a drug and delivered in a single image-guided step, have been developed to reduce the variability in a TACE procedure. DEB-TACE results in localization of drug to targeted tumors while minimizing systemic exposure to chemotherapeutics. Once localized in the tissue, drug is eluted from the DEB in a controlled manner and penetrates hundreds of microns of tissue from the DEB surface. Necrosis is evident surrounding a DEB in tissue days to months after therapy; however, the contribution of drug and ischemia is currently unknown. Future advances in DEB technology may include image-ability, DEB size tailored to tumor anatomy and drug combinations.
载药微球(DEB)经导管动脉化疗栓塞术(TACE)已在治疗实体瘤中应用了三十余年,它是一种在动脉内注入化疗药物后,再用微球进行栓塞的治疗方法。TACE 是一种治疗不可切除肝肿瘤的有效方法,尤其适用于肝癌等富血供肿瘤。近年来,开发了载药微球(DEB),其将均匀的栓塞材料加载药物,并在单次图像引导步骤中进行输送,以减少 TACE 操作中的变异性。DEB-TACE 将药物定位到靶向肿瘤,同时将化疗药物的全身暴露降至最低。药物一旦在组织中定位,就会从 DEB 中以受控的方式洗脱,并从 DEB 表面穿透数百微米的组织。在治疗后数天至数月,组织中可见 DEB 周围的坏死;然而,目前尚不清楚药物和缺血的作用。DEB 技术的未来进展可能包括成像能力、针对肿瘤解剖结构的 DEB 大小和药物组合。